{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:49:33Z","timestamp":1793026173201,"version":"4.5.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11864-025-01295-8","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:45:13Z","timestamp":1741149913000},"page":"197-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1692-3512","authenticated-orcid":false,"given":"Fatemeh","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-6657","authenticated-orcid":false,"given":"Mojtaba","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-5594","authenticated-orcid":false,"given":"Najmaldin","family":"Saki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"1295_CR1","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma.StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.; 2024."},{"issue":"1","key":"1295_CR2","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.4081\/hr.2017.6887","volume":"9","author":"A Nakaya","year":"2017","unstructured":"Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol Rep. 2017;9(1):6887.","journal-title":"Hematol Rep"},{"issue":"9","key":"1295_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221\u20137.","journal-title":"JAMA Oncol"},{"key":"1295_CR4","doi-asserted-by":"publisher","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9(1). https:\/\/doi.org\/10.3390\/medsci9010003.","DOI":"10.3390\/medsci9010003"},{"issue":"1","key":"1295_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/clinchem\/hvad148","volume":"70","author":"S R\u00f6gnvaldsson","year":"2024","unstructured":"R\u00f6gnvaldsson S, Thorsteinsd\u00f3ttir S, Kristinsson SY. Screening in Multiple Myeloma and Its Precursors: Are We There Yet? Clin Chem. 2024;70(1):128\u201339.","journal-title":"Clin Chem"},{"issue":"6","key":"1295_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/ijms19061721","volume":"19","author":"CY Soekojo","year":"2018","unstructured":"Soekojo CY, De Mel S, Ooi M, Yan B, Chng WJ. Potential clinical application of genomics in multiple myeloma. Int J Mol Sci. 2018;19(6):1721.","journal-title":"Int J Mol Sci"},{"key":"1295_CR7","unstructured":"Banu C, Moise A, Arion C, Coriu D, T\u0306nase A, Constantinescu I. Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. J Med Life. 2011;4(3):264."},{"issue":"1","key":"1295_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/1055-9965.EPI-08-0778","volume":"18","author":"BM Birmann","year":"2009","unstructured":"Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, et al. Insulin-like growth factor-1-and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomark Prev. 2009;18(1):282\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1295_CR9","doi-asserted-by":"crossref","unstructured":"Aghaei M, Khademi R, Far MAJ, Bahreiny SS, Mahdizade AH, Amirrajab N. Genetic Variants of Dectin-1 and their antifungal immunity impact in Hematologic Malignancies: A Comprehensive Systematic Review. Curr Res Trans Med. 2024:103460.","DOI":"10.1016\/j.retram.2024.103460"},{"issue":"Suppl 1","key":"1295_CR10","first-page":"S3","volume":"97","author":"U Goel","year":"2022","unstructured":"Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97(Suppl 1):S3-s25.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"1295_CR11","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.4081\/hr.2020.8956","volume":"12","author":"D Derudas","year":"2020","unstructured":"Derudas D, Capraro F, Martinelli G, Cerchione C. How I manage frontline transplant-ineligible multiple myeloma. Hematol Rep. 2020;12(Suppl 1):8956.","journal-title":"Hematol Rep"},{"issue":"3","key":"1295_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2217\/fon-2021-1072","volume":"18","author":"LN Gordan","year":"2022","unstructured":"Gordan LN, Marks SM, Xue M, Nagovski N, Lambert JH, Smith RE. Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting. Future Oncol. 2022;18(3):301\u20139.","journal-title":"Future Oncol"},{"key":"1295_CR13","doi-asserted-by":"crossref","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Jr., Baljevic M, Baz R, et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(12):1281\u2013301.","DOI":"10.6004\/jnccn.2023.0061"},{"issue":"7","key":"1295_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/bmt.2008.351","volume":"43","author":"AJ Vangsted","year":"2009","unstructured":"Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang A, et al. The polymorphism IL-1\u03b2 T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2009;43(7):539\u201345.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1295_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.61186\/ijbc.16.2.84","volume":"16","author":"SA Aghapour","year":"2024","unstructured":"Aghapour SA, Torabizadeh M, Bahreiny SS, Saki N, Jalali Far MA, Yousefi-Avarvand A, et al. Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review. Iran J Blood Cancer. 2024;16(2):84\u2013101.","journal-title":"Iran J Blood Cancer"},{"issue":"2","key":"1295_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-0609.2011.01696.x","volume":"88","author":"A Vangsted","year":"2012","unstructured":"Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol. 2012;88(2):93\u2013117.","journal-title":"Eur J Haematol"},{"key":"1295_CR17","doi-asserted-by":"publisher","unstructured":"Mahdizade AH, Bahreiny SS, Bastani M-N, Dabbagh MR, Aghaei M, Ali Malayeri F, et al. The influence of CDKAL1 (rs7754840) gene polymorphism on susceptibility to gestational diabetes mellitus in pregnant women: a systematic review and meta-analysis. Int J Diabetes Dev Countries. 2023. https:\/\/doi.org\/10.1007\/s13410-023-01272-7.","DOI":"10.1007\/s13410-023-01272-7"},{"issue":"1","key":"1295_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12967-023-04383-1","volume":"21","author":"N Saki","year":"2023","unstructured":"Saki N, Haybar H, Aghaei M. Subject: Motivation can be suppressed, but scientific ability cannot and should not be ignored. J Transl Med. 2023;21(1):520.","journal-title":"J Transl Med"},{"issue":"5","key":"1295_CR19","doi-asserted-by":"publisher","first-page":"E636","DOI":"10.1002\/ijc.27387","volume":"131","author":"NF Andersen","year":"2012","unstructured":"Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 2012;131(5):E636\u201342.","journal-title":"Int J Cancer"},{"key":"1295_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/B978-0-12-809633-8.20222-7","volume-title":"Encyclopedia of Bioinformatics and Computational Biology","author":"S Kaushik","year":"2019","unstructured":"Kaushik S, Kaushik S, Sharma D. Functional Genomics. In: Ranganathan S, Gribskov M, Nakai K, Sch\u00f6nbach C, editors. Encyclopedia of Bioinformatics and Computational Biology. Oxford: Academic Press; 2019. p. 118\u201333."},{"issue":"24","key":"1295_CR21","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"17","key":"1295_CR22","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, et al. US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559\u201363.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1295_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"S Ito","year":"2020","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265.","journal-title":"Cancers"},{"issue":"7\u20138","key":"1295_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/00498250701867889","volume":"38","author":"S-F Zhou","year":"2008","unstructured":"Zhou S-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38(7\u20138):802\u201332.","journal-title":"Xenobiotica"},{"issue":"3B","key":"1295_CR25","first-page":"2227","volume":"26","author":"H Obata","year":"2006","unstructured":"Obata H, Yahata T, Quan J, Sekine M, Tanaka K. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res. 2006;26(3B):2227\u201332.","journal-title":"Anticancer Res"},{"issue":"3","key":"1295_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/FPC.0b013e328323f680","volume":"19","author":"J-Y Yin","year":"2009","unstructured":"Yin J-Y, Huang Q, Yang Y, Zhang J-T, Zhong M-Z, Zhou H-H, Liu Z-Q. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1\/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics. 2009;19(3):206\u201316.","journal-title":"Pharmacogenet Genomics"},{"key":"1295_CR27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00277-010-0992-3","volume":"89","author":"G Buda","year":"2010","unstructured":"Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010;89:1133\u201340.","journal-title":"Ann Hematol"},{"issue":"1","key":"1295_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","volume":"24","author":"WA Teft","year":"2006","unstructured":"Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006;24(1):65\u201397.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"1295_CR29","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.4049\/jimmunol.165.11.6606","volume":"165","author":"T Kouki","year":"2000","unstructured":"Kouki T, Sawai Y, Gardine CA, Fisfalen M-E, Alegre M-L, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves\u2019 disease. J Immunol. 2000;165(11):6606\u201311.","journal-title":"J Immunol"},{"key":"1295_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00251-002-0429-9","volume":"54","author":"M M\u00e4urer","year":"2002","unstructured":"M\u00e4urer M, Loserth S, Kolb-M\u00e4urer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+ 49) alters T-cell activation. Immunogenetics. 2002;54:1\u20138.","journal-title":"Immunogenetics"},{"issue":"3","key":"1295_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/sj.gene.6363752","volume":"2","author":"A Ligers","year":"2001","unstructured":"Ligers A, Teleshova N, Masterman T, Huang W, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2(3):145\u201352.","journal-title":"Genes Immun"},{"issue":"4","key":"1295_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.gene.6363869","volume":"3","author":"X Wang","year":"2002","unstructured":"Wang X, Zhao X, Giscombe R, Lefvert A. A CTLA-4 gene polymorphism at position\u2212 318 in the promoter region affects the expression of protein. Genes Immun. 2002;3(4):233\u20134.","journal-title":"Genes Immun"},{"issue":"3","key":"1295_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00277-017-3203-7","volume":"97","author":"X-Y Qin","year":"2018","unstructured":"Qin X-Y, Lu J, Li G-X, Wen L, Liu Y, Xu L-P, et al. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Ann Hematol. 2018;97(3):485\u201395.","journal-title":"Ann Hematol"},{"issue":"5","key":"1295_CR34","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1073\/pnas.89.5.1890","volume":"89","author":"F Rousset","year":"1992","unstructured":"Rousset F, Garcia E, Defrance T, P\u00e9ronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992;89(5):1890\u20133.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1295_CR35","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/eji.1830240416","volume":"24","author":"J P\u00e9guet-Navarro","year":"1994","unstructured":"P\u00e9guet-Navarro J, Moulon C, Caux C, Dalbiez-Gauthier C, Banchereau J, Schmitt D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol. 1994;24(4):884\u201391.","journal-title":"Eur J Immunol"},{"issue":"4","key":"1295_CR36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.4049\/jimmunol.148.4.1143","volume":"148","author":"K Taga","year":"1992","unstructured":"Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol. 1992;148(4):1143\u20138.","journal-title":"J Immunol"},{"key":"1295_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","volume":"226","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205\u201318.","journal-title":"Immunol Rev"},{"issue":"4","key":"1295_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hon.2322","volume":"35","author":"T Kasamatsu","year":"2017","unstructured":"Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, et al. Polymorphism of IL-10 receptor \u03b2 affects the prognosis of multiple myeloma patients treated with thalidomide and\/or bortezomib. Hematol Oncol. 2017;35(4):711\u20138.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1295_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"51","key":"1295_CR40","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1038\/sj.onc.1209942","volume":"25","author":"DS Bass\u00e8res","year":"2006","unstructured":"Bass\u00e8res DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817\u201330.","journal-title":"Oncogene"},{"issue":"7","key":"1295_CR41","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","volume":"109","author":"PJ Jost","year":"2007","unstructured":"Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7):2700\u20137.","journal-title":"Blood"},{"issue":"9","key":"1295_CR42","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3324\/haematol.11199","volume":"92","author":"D Cilloni","year":"2007","unstructured":"Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92(9):1224\u20139.","journal-title":"Haematologica"},{"issue":"51","key":"1295_CR43","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1038\/sj.onc.1209938","volume":"25","author":"J Dutta","year":"2006","unstructured":"Dutta J, Fan Y, Gupta N, Fan G, G\u00e9linas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006;25(51):6800\u201316.","journal-title":"Oncogene"},{"issue":"6","key":"1295_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10875-005-8217-6","volume":"25","author":"JL Luo","year":"2005","unstructured":"Luo JL, Kamata H, Karin M. The anti-death machinery in IKK\/NF-kappaB signaling. J Clin Immunol. 2005;25(6):541\u201350.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1295_CR45","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ceb.2003.10.005","volume":"15","author":"E Burstein","year":"2003","unstructured":"Burstein E, Duckett CS. Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol. 2003;15(6):732\u20137.","journal-title":"Curr Opin Cell Biol"},{"issue":"2 Suppl 1","key":"1295_CR46","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1053\/j.seminoncol.2009.02.001","volume":"36","author":"KC Anderson","year":"2009","unstructured":"Anderson KC. Proteasome inhibitors in multiple myeloma. Semin Oncol. 2009;36(2 Suppl 1):S20\u20136.","journal-title":"Semin Oncol"},{"issue":"2","key":"1295_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","volume":"12","author":"CM Annunziata","year":"2007","unstructured":"Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115\u201330.","journal-title":"Cancer Cell"},{"issue":"2","key":"1295_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131\u201344.","journal-title":"Cancer Cell"},{"issue":"4","key":"1295_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrc1588","volume":"5","author":"C Nakanishi","year":"2005","unstructured":"Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5(4):297\u2013309.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1295_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0165-4608(02)00541-1","volume":"137","author":"KM Parker","year":"2002","unstructured":"Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, et al. Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet. 2002;137(1):43\u20138.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1\u20132","key":"1295_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.canlet.2006.02.001","volume":"246","author":"CF Spink","year":"2007","unstructured":"Spink CF, Gray LC, Davies FE, Morgan GJ, Bidwell JL. Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett. 2007;246(1\u20132):92\u20139.","journal-title":"Cancer Lett"},{"issue":"5","key":"1295_CR52","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3324\/haematol.2010.030577","volume":"96","author":"J Du","year":"2011","unstructured":"Du J, Huo J, Shi J, Yuan Z, Zhang C, Fu W, et al. Polymorphisms of nuclear factor-\u03baB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica. 2011;96(5):729\u201337.","journal-title":"Haematologica"},{"key":"1295_CR53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fonc.2017.00098","volume":"7","author":"AB Herrero","year":"2017","unstructured":"Herrero AB, Guti\u00e9rrez NC. Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival. Front Oncol. 2017;7:98.","journal-title":"Front Oncol"},{"issue":"12","key":"1295_CR54","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3399","volume":"12","author":"NJ Curtin","year":"2012","unstructured":"Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12(12):801\u201317.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1295_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41389-017-0025-3","volume":"7","author":"N Allocati","year":"2018","unstructured":"Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018;7(1):8.","journal-title":"Oncogenesis"},{"issue":"2","key":"1295_CR56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1681\/ASN.2008020227","volume":"20","author":"YS Lin","year":"2009","unstructured":"Lin YS, Hung SC, Wei YH, Tarng DC. GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(2):405\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"1295_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-60327-492-0_10","volume":"472","author":"MS Singh","year":"2009","unstructured":"Singh MS, Michael M. Role of xenobiotic metabolic enzymes in cancer epidemiology. Methods Mol Biol. 2009;472:243\u201364.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"1295_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1084\/jem.20102049","volume":"208","author":"AC Bulua","year":"2011","unstructured":"Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med. 2011;208(3):519\u201333.","journal-title":"J Exp Med"},{"issue":"6","key":"1295_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ccell.2017.11.015","volume":"32","author":"A El-Kenawi","year":"2017","unstructured":"El-Kenawi A, Ruffell B. Inflammation, ROS, and Mutagenesis. Cancer Cell. 2017;32(6):727\u20139.","journal-title":"Cancer Cell"},{"issue":"10","key":"1295_CR60","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.leukres.2008.03.001","volume":"32","author":"K K\u00e1d\u00e1r","year":"2008","unstructured":"K\u00e1d\u00e1r K, Kov\u00e1cs M, Kar\u00e1di I, Melegh B, Pocsai Z, Mikala G, et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 2008;32(10):1499\u2013504.","journal-title":"Leuk Res"},{"issue":"1","key":"1295_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1006\/jsre.1997.5040","volume":"69","author":"CS Wilson","year":"1997","unstructured":"Wilson CS, Seatter SC, Rodriguez JL, Bellingham J, Clair L, West MA. In vivo endotoxin tolerance: impaired LPS-stimulated TNF release of monocytes from patients with sepsis, but not SIRS. J Surg Res. 1997;69(1):101\u20136.","journal-title":"J Surg Res"},{"issue":"3","key":"1295_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1385\/MO:19:3:133","volume":"19","author":"V Jurisi\u0107","year":"2002","unstructured":"Jurisi\u0107 V, Colovi\u0107 M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol. 2002;19(3):133\u20139.","journal-title":"Med Oncol"},{"issue":"11","key":"1295_CR63","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"1295_CR64","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138.","journal-title":"Leukemia"},{"key":"1295_CR65","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3389\/fonc.2019.01056","volume":"9","author":"S Zmorzy\u0144ski","year":"2019","unstructured":"Zmorzy\u0144ski S, Popek-Marciniec S, Szudy-Szczyrek A, Wojcierowska-Litwin M, Korsze\u0144-Pilecka I, Chocholska S, et al. The Association of GSTT1, GSTM1, and TNF-\u03b1 Polymorphisms With the Risk and Outcome in Multiple Myeloma. Front Oncol. 2019;9:1056.","journal-title":"Front Oncol"},{"key":"1295_CR66","doi-asserted-by":"publisher","unstructured":"Zmorzynski S, Popek-Marciniec S, Biernacka B, Szudy-Szczyrek A, Chocholska S, Styk W, et al. In Vitro Low-Bortezomib Doses Induce Apoptosis and Independently Decrease the Activities of Glutathione S-Transferase and Glutathione Peroxidase in Multiple Myeloma, Taking into Account the GSTT1 and GSTM1 Gene Variants. Genes (Basel). 2024;15(3). https:\/\/doi.org\/10.3390\/genes15030387.","DOI":"10.3390\/genes15030387"},{"issue":"12","key":"1295_CR67","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00277-001-0398-3","volume":"80","author":"TM Moehler","year":"2001","unstructured":"Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol. 2001;80(12):695\u2013705.","journal-title":"Ann Hematol"},{"issue":"3","key":"1295_CR68","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","volume":"4","author":"N Giuliani","year":"2011","unstructured":"Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S. Angiogenesis and multiple myeloma. Cancer Microenviron. 2011;4(3):325\u201337.","journal-title":"Cancer Microenviron"},{"key":"1295_CR69","doi-asserted-by":"crossref","unstructured":"Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001;276(5):3222\u201330.","DOI":"10.1074\/jbc.M002016200"},{"issue":"12","key":"1295_CR70","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","volume":"15","author":"D Gupta","year":"2001","unstructured":"Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15(12):1950\u201361.","journal-title":"Leukemia"},{"issue":"10","key":"1295_CR71","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/sj.leu.2403084","volume":"17","author":"S Kumar","year":"2003","unstructured":"Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17(10):2025\u201331.","journal-title":"Leukemia"},{"issue":"10","key":"1295_CR72","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/sj.leu.2403076","volume":"17","author":"R Ria","year":"2003","unstructured":"Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003;17(10):1961\u20136.","journal-title":"Leukemia"},{"issue":"8","key":"1295_CR73","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","volume":"95","author":"B Dankbar","year":"2000","unstructured":"Dankbar B, Padr\u00f3 T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95(8):2630\u20136.","journal-title":"Blood"},{"issue":"2","key":"1295_CR74","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2141.2004.05299.x","volume":"128","author":"NF Andersen","year":"2005","unstructured":"Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, S\u00f8rensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 2005;128(2):210\u20137.","journal-title":"Br J Haematol"},{"issue":"8","key":"1295_CR75","first-page":"3111","volume":"6","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6(8):3111\u20136.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1295_CR76","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1158\/1535-7163.MCT-09-0302","volume":"8","author":"L Jain","year":"2009","unstructured":"Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8(9):2496\u2013508.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1295_CR77","first-page":"1363","volume":"93","author":"AB Brito","year":"2014","unstructured":"Brito AB, Louren\u00e7o GJ, Oliveira GB, De Souza CA, Vassallo J, Lima CS. Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Ann Hematol. 2014;93(8):1363\u20139.","journal-title":"Ann Hematol"},{"issue":"1","key":"1295_CR78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1756-9966-29-95","volume":"29","author":"L Jain","year":"2010","unstructured":"Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010;29(1):95.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1295_CR79","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00280-017-3323-8","volume":"80","author":"TM Sissung","year":"2017","unstructured":"Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, et al. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemother Pharmacol. 2017;80(1):217\u201321.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1295_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","volume":"17","author":"KD Kistler","year":"2017","unstructured":"Kistler KD, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, Chari A. Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective. Cohort Study Clin Lymphoma Myeloma Leuk. 2017;17(2):89-96.e3.","journal-title":"Cohort Study Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1295_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.93","volume":"5","author":"S Atrash","year":"2015","unstructured":"Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, Usmani SZ. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5(1): e272.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1295_CR82","doi-asserted-by":"publisher","first-page":"64","DOI":"10.15420\/ecr.2017:17:2","volume":"13","author":"A Koutsoukis","year":"2018","unstructured":"Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I. Cardio-oncology: A Focus on Cardiotoxicity. Eur Cardiol. 2018;13(1):64\u20139.","journal-title":"Eur Cardiol"},{"issue":"8","key":"1295_CR83","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","volume":"11","author":"ML Henry","year":"2018","unstructured":"Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging. 2018;11(8):1084\u201393.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1295_CR84","doi-asserted-by":"publisher","first-page":"1181806","DOI":"10.3389\/fcvm.2023.1181806","volume":"10","author":"M Tantawy","year":"2023","unstructured":"Tantawy M, Yang G, Algubelli RR, DeAvila G, Rubinstein SM, Cornell RF, et al. Whole-Exome sequencing analysis identified TMSB10\/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. Front Cardiovasc Med. 2023;10:1181806.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"1295_CR85","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1111\/cas.14538","volume":"111","author":"K Miyazato","year":"2020","unstructured":"Miyazato K, Tahara H, Hayakawa Y. Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells. Cancer Sci. 2020;111(8):2770\u20138.","journal-title":"Cancer Sci"},{"issue":"3","key":"1295_CR86","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/1389450116666150304104315","volume":"18","author":"JF Zeidner","year":"2017","unstructured":"Zeidner JF, Foster MC. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML). Curr Drug Targets. 2017;18(3):304\u201314.","journal-title":"Curr Drug Targets"},{"key":"1295_CR87","doi-asserted-by":"crossref","unstructured":"Charli\u0144ski G, Vesole DH, Jurczyszyn A. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. Cancers (Basel). 2021;13(18).","DOI":"10.3390\/cancers13184666"},{"issue":"8","key":"1295_CR88","first-page":"564","volume":"16","author":"S Gandolfi","year":"2018","unstructured":"Gandolfi S, Vekstein C, Laubach JP, O\u2019Brien A, Masone K, Munshi NC, et al. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018;16(8):564\u201374.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"1295_CR89","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.173.3.699","volume":"173","author":"EP Sampaio","year":"1991","unstructured":"Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699\u2013703.","journal-title":"J Exp Med"},{"key":"1295_CR90","doi-asserted-by":"publisher","unstructured":"Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int J Dermatol. 1980;19(6):318\u201322. https:\/\/doi.org\/10.1111\/j.1365-4362.1980.tb00342.x.","DOI":"10.1111\/j.1365-4362.1980.tb00342.x"},{"issue":"2","key":"1295_CR91","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/infdis\/168.2.408","volume":"168","author":"EP Sampaio","year":"1993","unstructured":"Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168(2):408\u201314.","journal-title":"J Infect Dis"},{"issue":"2","key":"1295_CR92","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1074\/jbc.273.2.974","volume":"273","author":"T Raabe","year":"1998","unstructured":"Raabe T, Bukrinsky M, Currie RA. Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide. J Biol Chem. 1998;273(2):974\u201380.","journal-title":"J Biol Chem"},{"issue":"5","key":"1295_CR93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0161-5890(97)00052-7","volume":"34","author":"KM Kroeger","year":"1997","unstructured":"Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34(5):391\u20139.","journal-title":"Mol Immunol"},{"issue":"7","key":"1295_CR94","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1073\/pnas.94.7.3195","volume":"94","author":"AG Wilson","year":"1997","unstructured":"Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94(7):3195\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1295_CR95","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1182\/blood.V100.6.2263","volume":"100","author":"K Neben","year":"2002","unstructured":"Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002;100(6):2263\u20135.","journal-title":"Blood"},{"issue":"11","key":"1295_CR96","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.leukres.2010.01.011","volume":"34","author":"J Du","year":"2010","unstructured":"Du J, Yuan Z, Zhang C, Fu W, Jiang H, Chen B, Hou J. Role of the TNF-\u03b1 promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res. 2010;34(11):1453\u20138.","journal-title":"Leuk Res"},{"key":"1295_CR97","doi-asserted-by":"publisher","unstructured":"Allegra A, Casciaro M, Barone P, Musolino C, Gangemi S. Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma. Cancers (Basel). 2022;14(11). https:\/\/doi.org\/10.3390\/cancers14112597.","DOI":"10.3390\/cancers14112597"},{"issue":"2","key":"1295_CR98","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.cyto.2015.07.015","volume":"76","author":"CS Metzger","year":"2015","unstructured":"Metzger CS, Koutsimpelas D, Brieger J. Transcriptional regulation of the VEGF gene in dependence of individual genomic variations. Cytokine. 2015;76(2):519\u201326.","journal-title":"Cytokine"},{"key":"1295_CR99","doi-asserted-by":"crossref","unstructured":"Lopes-Aguiar L, Delamain MT, Brito ABC, Louren\u00e7o GJ, Costa EFD, Oliveira GB, et al. VEGF, VEGFR2 and GSTM1 polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era. Blood. 2016;128(22):4457-.","DOI":"10.1182\/blood.V128.22.4457.4457"},{"key":"1295_CR100","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-10-404","volume":"10","author":"AJ Vangsted","year":"2010","unstructured":"Vangsted AJ, S\u00f8eby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, et al. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer. 2010;10:404.","journal-title":"BMC Cancer"},{"issue":"6","key":"1295_CR101","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","volume":"392","author":"UM Zanger","year":"2008","unstructured":"Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093\u2013108.","journal-title":"Anal Bioanal Chem"},{"issue":"9","key":"1295_CR102","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3324\/haematol.11319","volume":"92","author":"Y Li","year":"2007","unstructured":"Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, et al. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica. 2007;92(9):1246\u20139.","journal-title":"Haematologica"},{"issue":"Pt 5","key":"1295_CR103","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1242\/jcs.039842","volume":"123","author":"PD McCrea","year":"2010","unstructured":"McCrea PD, Gu D. The catenin family at a glance. J Cell Sci. 2010;123(Pt 5):637\u201342.","journal-title":"J Cell Sci"},{"issue":"10","key":"1295_CR104","doi-asserted-by":"publisher","first-page":"9439","DOI":"10.1007\/s13277-014-2433-8","volume":"35","author":"J Tian","year":"2014","unstructured":"Tian J, He H, Lei G. Wnt\/\u03b2-catenin pathway in bone cancers. Tumour Biol. 2014;35(10):9439\u201345.","journal-title":"Tumour Biol"},{"issue":"13","key":"1295_CR105","doi-asserted-by":"publisher","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","volume":"286","author":"CC Bjorklund","year":"2011","unstructured":"Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, et al. Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286(13):11009\u201320.","journal-title":"J Biol Chem"},{"issue":"12","key":"1295_CR106","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.leukres.2015.10.007","volume":"39","author":"A Butrym","year":"2015","unstructured":"Butrym A, Rybka J, \u0141acina P, G\u0119bura K, Frontkiewicz D, Bogunia-Kubik K, Mazur G. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res. 2015;39(12):1462\u20136.","journal-title":"Leuk Res"},{"issue":"3","key":"1295_CR107","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/10428194.2019.1689391","volume":"61","author":"E Iskierka-Ja\u017cd\u017cewska","year":"2020","unstructured":"Iskierka-Ja\u017cd\u017cewska E, Canzian F, St\u0119pie\u0144 A, Martino A, Campa D, Stein A, et al. Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed\/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leuk Lymphoma. 2020;61(3):699\u2013706.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1295_CR108","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","volume":"121","author":"A Broyl","year":"2013","unstructured":"Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121(4):624\u20137.","journal-title":"Blood"},{"issue":"1","key":"1295_CR109","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","volume":"38","author":"SR Schuster","year":"2014","unstructured":"Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38(1):23\u20138.","journal-title":"Leuk Res"},{"issue":"5","key":"1295_CR110","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/leu.2013.315","volume":"28","author":"A Thakurta","year":"2014","unstructured":"Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28(5):1129\u201331.","journal-title":"Leukemia"},{"issue":"1","key":"1295_CR111","doi-asserted-by":"publisher","first-page":"14884","DOI":"10.1038\/s41598-019-51446-9","volume":"9","author":"PA Huang","year":"2019","unstructured":"Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, et al. Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Sci Rep. 2019;9(1):14884.","journal-title":"Sci Rep"},{"key":"1295_CR112","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.13197","volume":"168","author":"G Varga","year":"2015","unstructured":"Varga G, Mikala G, Andrikovics H, et al. NFKB1 -94ins\/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. Br J Haematol. 2015;168:679\u201388.","journal-title":"Br J Haematol."},{"issue":"2","key":"1295_CR113","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397.","journal-title":"Cell"},{"issue":"9","key":"1295_CR114","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/leu.2014.155","volume":"28","author":"A Rocci","year":"2014","unstructured":"Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014;28(9):1922\u20136.","journal-title":"Leukemia"},{"issue":"21","key":"1295_CR115","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/blood.V124.21.2045.2045","volume":"124","author":"CF de Larrea","year":"2014","unstructured":"de Larrea CF, D\u00edaz T, Cibeira MT, Tovar N, Navarro A, Rosi\u00f1ol L, et al. Salvage therapy for multiple myeloma with lenalidomide-based regimens: impact of single nucleotide polymorphisms related to miRNA pathways. Blood. 2014;124(21):2045.","journal-title":"Blood"},{"issue":"6","key":"1295_CR116","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0093-7754(01)90036-3","volume":"28","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol. 2001;28(6):626\u201333.","journal-title":"Semin Oncol"},{"key":"1295_CR117","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.leukres.2015.10.007","volume":"39","author":"A Butrym","year":"2015","unstructured":"Butrym A, Rybka J, \u0141acina P, et al. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res. 2015;39:1462\u20136.","journal-title":"Leuk Res"},{"key":"1295_CR118","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/blood.V124.21.2045.2045","volume":"124","author":"CF de Larrea","year":"2014","unstructured":"de Larrea CF, D\u00edaz T, Cibeira MT, et al. Salvage therapy for multiple myeloma with lenalidomide-based regimens: impact of single nucleotide polymorphisms related to miRNA pathways. Blood. 2014;124:2045.","journal-title":"Blood"},{"issue":"16","key":"1295_CR119","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617\u201329.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1295_CR120","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc2867","volume":"10","author":"BM Ryan","year":"2010","unstructured":"Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389\u2013402.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1295_CR121","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3324\/haematol.2013.093500","volume":"99","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99(3):511\u20138.","journal-title":"Haematologica"},{"issue":"8","key":"1295_CR122","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/ijc.29199","volume":"136","author":"M Hao","year":"2015","unstructured":"Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015;136(8):1835\u201344.","journal-title":"Int J Cancer"},{"issue":"3","key":"1295_CR123","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.18632\/oncotarget.2761","volume":"6","author":"A Navarro","year":"2015","unstructured":"Navarro A, D\u00edaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, et al. A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget. 2015;6(3):1874\u201383.","journal-title":"Oncotarget"},{"key":"1295_CR124","doi-asserted-by":"publisher","unstructured":"Sanz-Solas A, Labrador J, Alcaraz R, Cuevas B, Vinuesa R, Cuevas MV, Saiz-Rodr\u00edguez M. Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives. J Personalized Med. 2023; 13(4). https:\/\/doi.org\/10.3390\/jpm13040695.","DOI":"10.3390\/jpm13040695"},{"key":"1295_CR125","doi-asserted-by":"publisher","first-page":"1351565","DOI":"10.3389\/fphar.2024.1351565","volume":"15","author":"M Pelon","year":"2024","unstructured":"Pelon M, Krzeminski P, Tracz-Gaszewska Z, Misiewicz-Krzeminska I. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells. Front Pharmacol. 2024;15:1351565.","journal-title":"Front Pharmacol"},{"key":"1295_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.819127","volume":"11","author":"D Pan","year":"2021","unstructured":"Pan D, Richter J. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Front Oncol. 2021;11: 819127.","journal-title":"Front Oncol"},{"key":"1295_CR127","doi-asserted-by":"publisher","unstructured":"Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, et al. Next-Generation Sequencing Technology: Curr Trends Adv Biol (Basel). 2023;12(7). https:\/\/doi.org\/10.3390\/biology12070997.","DOI":"10.3390\/biology12070997"},{"key":"1295_CR128","doi-asserted-by":"crossref","unstructured":"Study Tests Targeted Drugs for Multiple Myeloma. Cancer Discov. 2019;9(4):459-.","DOI":"10.1158\/2159-8290.CD-NB2019-014"},{"issue":"7","key":"1295_CR129","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660\u201375.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01295-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T22:38:07Z","timestamp":1742337487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01295-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"27 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}